Photos: Researchers move closer to new vaccine for killer TB

Scientists said they are closing in on a new game-changing vaccine for tuberculosis, the world's deadliest infectious disease that claimed some 1.5 million lives last year. The existing Bacille-Calmette-Guerin (BCG) vaccine -- licensed for humans in 1921 -- is only proven to be effective for children under five for limited forms of tuberculosis. In a trial in three African nations, GlaxoSmithKline said its vaccine had 50% effectiveness three years after it was given to participants who already have TB bacteria but have not fallen ill from the disease, GSK Vaccines' chief medical officer Thomas Breuer said in a statement released at a conference on lung health in Hyderabad, India.

Updated On Oct 31, 2019 11:09 PM IST 9 Photos
Copy Link
1 / 9
A doctor checks the chest X-ray of a patient in the tuberculosis (TB) department of the government-run Osmania General Hospital in Hyderabad. Scientists said they are closing in on a vaccine for tuberculosis, the world’s deadliest infectious disease that claimed some 1.5 million lives last year. (Noah Seelam / AFP)

A doctor checks the chest X-ray of a patient in the tuberculosis (TB) department of the government-run Osmania General Hospital in Hyderabad. Scientists said they are closing in on a vaccine for tuberculosis, the world’s deadliest infectious disease that claimed some 1.5 million lives last year. (Noah Seelam / AFP)

Updated on Oct 31, 2019 11:09 PM IST
Copy Link
2 / 9
A chronic lung disease that is curable, TB was one of the top 10 killers worldwide last year, particularly in developing countries. The existing Bacille Calmette Guerin (BCG) vaccine licensed for humans in 1921 is only proven to be effective for children under five for limited forms of tuberculosis. It does not protect against pulmonary TB, the most common form of the disease among adults and teens. (Noah Seelam / AFP)

A chronic lung disease that is curable, TB was one of the top 10 killers worldwide last year, particularly in developing countries. The existing Bacille Calmette Guerin (BCG) vaccine licensed for humans in 1921 is only proven to be effective for children under five for limited forms of tuberculosis. It does not protect against pulmonary TB, the most common form of the disease among adults and teens. (Noah Seelam / AFP)

Updated on Oct 31, 2019 11:09 PM IST
Copy Link
3 / 9
A doctor checks a suspected tuberculosis (TB) patient at a DOTS (directly observed treatment, short-course) Centre in New Delhi. In a trial in three African nations, GlaxoSmithKline said its new vaccine had 50 percent effectiveness three years after it was given to participants who already have TB bacteria but have not fallen ill from the disease. (Money Sharma / AFP)

A doctor checks a suspected tuberculosis (TB) patient at a DOTS (directly observed treatment, short-course) Centre in New Delhi. In a trial in three African nations, GlaxoSmithKline said its new vaccine had 50 percent effectiveness three years after it was given to participants who already have TB bacteria but have not fallen ill from the disease. (Money Sharma / AFP)

Updated on Oct 31, 2019 11:09 PM IST
Copy Link
4 / 9
Patients wait for their turn to get their daily dose of medicine at a DOTS centre in New Delhi. Campaigners said the trial in Kenya, South Africa and Zambia, involving more than 3,000 adults, was a crucial step amid a push for more funding for TB research. (Money Sharma / AFP)

Patients wait for their turn to get their daily dose of medicine at a DOTS centre in New Delhi. Campaigners said the trial in Kenya, South Africa and Zambia, involving more than 3,000 adults, was a crucial step amid a push for more funding for TB research. (Money Sharma / AFP)

Updated on Oct 31, 2019 11:09 PM IST
Copy Link
5 / 9
A medical supervisor (C) holds a packet of medicine to treat TB as he talks with a patient in the government-run Osmania General Hospital. South African Tuberculosis Vaccine Initiative director Mark Hatherill said a vaccine would be “the only way in the short-term to interrupt TB transmission and get control of the epidemic.” (Noah Seelam / AFP)

A medical supervisor (C) holds a packet of medicine to treat TB as he talks with a patient in the government-run Osmania General Hospital. South African Tuberculosis Vaccine Initiative director Mark Hatherill said a vaccine would be “the only way in the short-term to interrupt TB transmission and get control of the epidemic.” (Noah Seelam / AFP)

Updated on Oct 31, 2019 11:09 PM IST
Copy Link
6 / 9
Ann Ginsberg, of the International AIDS Vaccine Initiative which has been taking part in the research, said 15 possible vaccines are at various stages of development around the world but this was the most “exciting”. If successful, the vaccine could “avert tens of millions of new cases of TB and save millions of lives globally.” (Money Sharma / AFP)

Ann Ginsberg, of the International AIDS Vaccine Initiative which has been taking part in the research, said 15 possible vaccines are at various stages of development around the world but this was the most “exciting”. If successful, the vaccine could “avert tens of millions of new cases of TB and save millions of lives globally.” (Money Sharma / AFP)

Updated on Oct 31, 2019 11:09 PM IST
Copy Link
7 / 9
“We are one more cautious, but exciting, step closer to a vaccine for tuberculosis,” said Paula Fujiwara, scientific director of the Paris-based International Union Against Tuberculosis and Lung Disease. The results have to be further tested in longer and larger trials across broader ranges of populations and countries, the scientists said in the New England Journal of Medicine, where the report was published. (Money Sharma / AFP)

“We are one more cautious, but exciting, step closer to a vaccine for tuberculosis,” said Paula Fujiwara, scientific director of the Paris-based International Union Against Tuberculosis and Lung Disease. The results have to be further tested in longer and larger trials across broader ranges of populations and countries, the scientists said in the New England Journal of Medicine, where the report was published. (Money Sharma / AFP)

Updated on Oct 31, 2019 11:09 PM IST
Copy Link
8 / 9
About one in four people worldwide carry latent TB, meaning they are infected with the bacteria but are not sick and cannot transmit the disease. Between five to 15 percent develop active TB. Those with compromised immune systems such as people with HIV are more vulnerable to falling sick. (Noah Seelam / AFP)

About one in four people worldwide carry latent TB, meaning they are infected with the bacteria but are not sick and cannot transmit the disease. Between five to 15 percent develop active TB. Those with compromised immune systems such as people with HIV are more vulnerable to falling sick. (Noah Seelam / AFP)

Updated on Oct 31, 2019 11:09 PM IST
Copy Link
9 / 9
The announcement came as thousands of researchers, TB survivors and activists gathered in the southern Indian city of Hyderabad for a global conference on lung health. India accounts for a quarter of the world’s TB cases and Prime Minister Narendra Modi has set an ambitious target of ending the epidemic by 2025. (Money Sharma / AFP)

The announcement came as thousands of researchers, TB survivors and activists gathered in the southern Indian city of Hyderabad for a global conference on lung health. India accounts for a quarter of the world’s TB cases and Prime Minister Narendra Modi has set an ambitious target of ending the epidemic by 2025. (Money Sharma / AFP)

Updated on Oct 31, 2019 11:09 PM IST
Copy Link
SHARE
Story Saved
×
Saved Articles
My Reads
Sign out
New Delhi 0C
Sunday, October 17, 2021